A Case Series of Eight Mucormycosis Patients during SARS-CoV-2 –Pandemic

The outbreak of opportunistic fungal infections such as mucormycosis has been a critical issue following coronavirus disease 19 (COVID-19). Mucormycosis is happened by the fungal group Mucorales and commonly affects immunocompromised patients. To date, COVID-19-associated mucormycosis (CAM) is bein...

Full description

Bibliographic Details
Main Authors: Hedyieh Karbasforooshan, Batool Zarei, Mahdi Jannati, Ghazaleh Elahabadi, Sepideh Elyasi, Ali Akbar Heydari
Format: Article
Language:English
Published: Research Center for Rational Use of Drugs (RCRUD) 2023-09-01
Series:Journal of Pharmaceutical Care
Subjects:
Online Access:https://jpc.tums.ac.ir/index.php/jpc/article/view/600
_version_ 1797658879627100160
author Hedyieh Karbasforooshan
Batool Zarei
Mahdi Jannati
Ghazaleh Elahabadi
Sepideh Elyasi
Ali Akbar Heydari
author_facet Hedyieh Karbasforooshan
Batool Zarei
Mahdi Jannati
Ghazaleh Elahabadi
Sepideh Elyasi
Ali Akbar Heydari
author_sort Hedyieh Karbasforooshan
collection DOAJ
description The outbreak of opportunistic fungal infections such as mucormycosis has been a critical issue following coronavirus disease 19 (COVID-19). Mucormycosis is happened by the fungal group Mucorales and commonly affects immunocompromised patients. To date, COVID-19-associated mucormycosis (CAM) is being reported in several countries. It should be noted that CAM has been started in patients approximately within two to three weeks after the onset of COVID-19. However, here, in one case, fungal symptoms appeared after just one week. In patients with mucormycosis due to this enigmatic infection, the sinuses were most commonly affected, followed by the orbit, nose, and finally the brain. All cases received glucocorticoids as a part of viral therapy. Diabetes mellitus (DM) was reported in all but one case in which COVID-19 was detected, without complications, and this may be the sole predisposing agent.  Therefore, in this manuscript, we reported eight cases of COVID-19-induced mucormycosis. Although one case experienced evacuation of the right eye, others discharge with promising outcomes after receiving surgical debridement and proper anti-fungal treatment including, amphotericin B, caspofungin, and posaconazole.
first_indexed 2024-03-11T18:05:42Z
format Article
id doaj.art-01f88a8e33204b58ab015704859e4c29
institution Directory Open Access Journal
issn 2322-4630
2322-4509
language English
last_indexed 2024-03-11T18:05:42Z
publishDate 2023-09-01
publisher Research Center for Rational Use of Drugs (RCRUD)
record_format Article
series Journal of Pharmaceutical Care
spelling doaj.art-01f88a8e33204b58ab015704859e4c292023-10-17T05:30:36ZengResearch Center for Rational Use of Drugs (RCRUD)Journal of Pharmaceutical Care2322-46302322-45092023-09-01113A Case Series of Eight Mucormycosis Patients during SARS-CoV-2 –PandemicHedyieh Karbasforooshan0Batool Zarei1Mahdi Jannati2Ghazaleh Elahabadi3Sepideh Elyasi4Ali Akbar Heydari5Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.Department of Infectious Disease, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. The outbreak of opportunistic fungal infections such as mucormycosis has been a critical issue following coronavirus disease 19 (COVID-19). Mucormycosis is happened by the fungal group Mucorales and commonly affects immunocompromised patients. To date, COVID-19-associated mucormycosis (CAM) is being reported in several countries. It should be noted that CAM has been started in patients approximately within two to three weeks after the onset of COVID-19. However, here, in one case, fungal symptoms appeared after just one week. In patients with mucormycosis due to this enigmatic infection, the sinuses were most commonly affected, followed by the orbit, nose, and finally the brain. All cases received glucocorticoids as a part of viral therapy. Diabetes mellitus (DM) was reported in all but one case in which COVID-19 was detected, without complications, and this may be the sole predisposing agent.  Therefore, in this manuscript, we reported eight cases of COVID-19-induced mucormycosis. Although one case experienced evacuation of the right eye, others discharge with promising outcomes after receiving surgical debridement and proper anti-fungal treatment including, amphotericin B, caspofungin, and posaconazole. https://jpc.tums.ac.ir/index.php/jpc/article/view/600COVID-19; Fugal Infection; Mucormycosis
spellingShingle Hedyieh Karbasforooshan
Batool Zarei
Mahdi Jannati
Ghazaleh Elahabadi
Sepideh Elyasi
Ali Akbar Heydari
A Case Series of Eight Mucormycosis Patients during SARS-CoV-2 –Pandemic
Journal of Pharmaceutical Care
COVID-19; Fugal Infection; Mucormycosis
title A Case Series of Eight Mucormycosis Patients during SARS-CoV-2 –Pandemic
title_full A Case Series of Eight Mucormycosis Patients during SARS-CoV-2 –Pandemic
title_fullStr A Case Series of Eight Mucormycosis Patients during SARS-CoV-2 –Pandemic
title_full_unstemmed A Case Series of Eight Mucormycosis Patients during SARS-CoV-2 –Pandemic
title_short A Case Series of Eight Mucormycosis Patients during SARS-CoV-2 –Pandemic
title_sort case series of eight mucormycosis patients during sars cov 2 pandemic
topic COVID-19; Fugal Infection; Mucormycosis
url https://jpc.tums.ac.ir/index.php/jpc/article/view/600
work_keys_str_mv AT hedyiehkarbasforooshan acaseseriesofeightmucormycosispatientsduringsarscov2pandemic
AT batoolzarei acaseseriesofeightmucormycosispatientsduringsarscov2pandemic
AT mahdijannati acaseseriesofeightmucormycosispatientsduringsarscov2pandemic
AT ghazalehelahabadi acaseseriesofeightmucormycosispatientsduringsarscov2pandemic
AT sepidehelyasi acaseseriesofeightmucormycosispatientsduringsarscov2pandemic
AT aliakbarheydari acaseseriesofeightmucormycosispatientsduringsarscov2pandemic
AT hedyiehkarbasforooshan caseseriesofeightmucormycosispatientsduringsarscov2pandemic
AT batoolzarei caseseriesofeightmucormycosispatientsduringsarscov2pandemic
AT mahdijannati caseseriesofeightmucormycosispatientsduringsarscov2pandemic
AT ghazalehelahabadi caseseriesofeightmucormycosispatientsduringsarscov2pandemic
AT sepidehelyasi caseseriesofeightmucormycosispatientsduringsarscov2pandemic
AT aliakbarheydari caseseriesofeightmucormycosispatientsduringsarscov2pandemic